Skip to main content

Table 1 Characteristics of subjects who underwent 18F-florbetapir-positron emission tomography (amyloid-PET) and lumbar puncture (LP) within a 365-day interval

From: Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes

 

Amyloid-PET positive*

Amyloid-PET negative°

p value

n

37

7

 

Age

71.4 ± 7.5

72.9 ± 3.6

0.76

M:F

13:24

3:4

0.69

Interval LP/amyloid-PET (days)

168.6 ± 119.5

246.4 ± 115.1

0.35

Aβ1-42 (pg/ml)

542.2 ± 119.2

842.3 ± 341.9

0.001

t-tau (pg/ml)

700.5 ± 493.3

681.3 ± 593.1

0.83

p-tau (pg/ml)

83.9 ± 38.5

67 ± 31.8

0.34

t-tau/Aβ1-42

1.30 ± 0.9

0.90 ± 1.0

0.13

p-tau/Aβ1-42

0.15 ± 0.07

0.09 ± 0.06

0.01

Amyloid-PET SUVR GM mean

1.47 ± 0.21

0.98 ± 0.10

< 0.0001

Amyloid-PET SUVR Ant Cing

1.49 ± 025

0.99 ± 0.16

< 0.0001

Amyloid-PET SUVR frontal

1.36 ± 0.25

0.89 ± 0.19

< 0.0001

Amyloid-PET SUVR parietal

1.28 ± 0.19

1.04 ± 0.15

0.005

Amyloid-PET SUVR post Cing

1.55 ± 0.22

0.97 ± 0.20

< 0.0001

Amyloid-PET SUVR precuneus

1.61 ± 0.27

1.02 ± 0.22

< 0.0001

Amyloid-PET SUVR temporal

1.50 ± 0.19

1.04 ± 0.15

< 0.0001

  1. Data are expressed as mean ± SD, unless otherwise specified. p values by unpaired t test. *Among amyloid-PET-positive patients, 14 were diagnosed of Alzheimer’s disease, 2 cerebral amyloid angiopathy, 20 mild cognitive impairment (MCI) and 1 mixed dementia. °Four amyloid-PET-negative patients had a diagnosis of MCI, 1 frontotemporal dementia, 1 mixed dementia and 1 dysthymic dementia
  2. All significant data (p value < 0.05) are presented in italic
  3. Abbreviations: M males, F females, Aβ1-42 amyloid-β1-42, t-tau total tau, p-tau phosphorylated tau, SUVR standardised uptake value relative ratio, GM grey matter